HIMS
The FDA just crashed the party
Hims & Hers got dinged after the FDA warned telehealth companies and compounding pharmacies about unapproved weight-loss drugs. The agency specifically called out versions of semaglutide, tirzepatide, retatrutide and cagrilintide — basically the alphabet soup of the GLP-1 boom.
Why investors are twitching
If you’re wondering why the stock slipped, here’s the short version: this isn’t some vague industry hand-wave. It lands squarely on a business that’s become a big part of the Hims growth story. When the regulator starts saying certain ingredients can’t legally be used in compounding, that’s not exactly the kind of plot twist management puts on the holiday card.
The real risk here
The FDA said retatrutide and cagrilintide cannot legally be used in compounding, and it has already warned companies marketing unapproved retatrutide directly to consumers. Translation: the rules of the game may be getting tighter just as demand for weight-loss meds has turned into a gold rush.
Big picture
Hims is still selling the “modern healthcare, but make it convenient” story. The catch is that convenience gets a lot less cute when regulators start circling. For investors, the question is whether this is a one-day headline bruise or the start of a more annoying compliance hangover.